These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 12496865

  • 1. The microtubule-stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cells.
    Sepp-Lorenzino L, Balog A, Su DS, Meng D, Timaul N, Scher HI, Danishefsky SJ, Rosen N.
    Prostate Cancer Prostatic Dis; 1999 Jan; 2(1):41-52. PubMed ID: 12496865
    [Abstract] [Full Text] [Related]

  • 2. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest.
    Kamath K, Jordan MA.
    Cancer Res; 2003 Sep 15; 63(18):6026-31. PubMed ID: 14522931
    [Abstract] [Full Text] [Related]

  • 3. Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization.
    Feyen F, Cachoux F, Gertsch J, Wartmann M, Altmann KH.
    Acc Chem Res; 2008 Jan 15; 41(1):21-31. PubMed ID: 18159935
    [Abstract] [Full Text] [Related]

  • 4. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.
    Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, Goetz M, Lazarides E, Woods CM.
    Cancer Res; 1995 Jun 01; 55(11):2325-33. PubMed ID: 7757983
    [Abstract] [Full Text] [Related]

  • 5. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents.
    Mooberry SL, Tien G, Hernandez AH, Plubrukarn A, Davidson BS.
    Cancer Res; 1999 Feb 01; 59(3):653-60. PubMed ID: 9973214
    [Abstract] [Full Text] [Related]

  • 6. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone.
    Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L, Skuballa W, Vivet S, Lichtner RB, Vicencio JM, Panaretakis T, Siemeister G, Lage H, Nanty L, Hammer S, Mittelstaedt K, Winsel S, Eschenbrenner J, Castedo M, Demarche C, Klar U, Kroemer G.
    Cancer Res; 2008 Jul 01; 68(13):5301-8. PubMed ID: 18593931
    [Abstract] [Full Text] [Related]

  • 7. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.
    Hofstetter B, Vuong V, Broggini-Tenzer A, Bodis S, Ciernik IF, Fabbro D, Wartmann M, Folkers G, Pruschy M.
    Clin Cancer Res; 2005 Feb 15; 11(4):1588-96. PubMed ID: 15746064
    [Abstract] [Full Text] [Related]

  • 8. Activity of epothilones.
    Kolman A.
    Curr Opin Investig Drugs; 2005 Jun 15; 6(6):616-22. PubMed ID: 15988913
    [Abstract] [Full Text] [Related]

  • 9. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
    Peterson JK, Tucker C, Favours E, Cheshire PJ, Creech J, Billups CA, Smykla R, Lee FY, Houghton PJ.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 1):6950-8. PubMed ID: 16203787
    [Abstract] [Full Text] [Related]

  • 10. Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma.
    Alberti C.
    Eur Rev Med Pharmacol Sci; 2013 Jun 01; 17(12):1658-64. PubMed ID: 23832735
    [Abstract] [Full Text] [Related]

  • 11. Gene expression and mitotic exit induced by microtubule-stabilizing drugs.
    Chen JG, Yang CP, Cammer M, Horwitz SB.
    Cancer Res; 2003 Nov 15; 63(22):7891-9. PubMed ID: 14633718
    [Abstract] [Full Text] [Related]

  • 12. Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs.
    Chen JG, Horwitz SB.
    Cancer Res; 2002 Apr 01; 62(7):1935-8. PubMed ID: 11929805
    [Abstract] [Full Text] [Related]

  • 13. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, Vite G.
    Cancer Chemother Pharmacol; 2008 Dec 01; 63(1):157-66. PubMed ID: 18347795
    [Abstract] [Full Text] [Related]

  • 14. Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
    Cortes J, Baselga J.
    Oncologist; 2007 Mar 01; 12(3):271-80. PubMed ID: 17405891
    [Abstract] [Full Text] [Related]

  • 15. Taccalonolides E and A: Plant-derived steroids with microtubule-stabilizing activity.
    Tinley TL, Randall-Hlubek DA, Leal RM, Jackson EM, Cessac JW, Quada JC, Hemscheidt TK, Mooberry SL.
    Cancer Res; 2003 Jun 15; 63(12):3211-20. PubMed ID: 12810650
    [Abstract] [Full Text] [Related]

  • 16. Epothilones: mechanism of action and biologic activity.
    Goodin S, Kane MP, Rubin EH.
    J Clin Oncol; 2004 May 15; 22(10):2015-25. PubMed ID: 15143095
    [Abstract] [Full Text] [Related]

  • 17. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)).
    Kowalski RJ, Giannakakou P, Hamel E.
    J Biol Chem; 1997 Jan 24; 272(4):2534-41. PubMed ID: 8999970
    [Abstract] [Full Text] [Related]

  • 18. Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer.
    Sepp-Lorenzino L, Tjaden G, Moasser MM, Timaul N, Ma Z, Kohl NE, Gibbs JB, Oliff A, Rosen N, Scher HI.
    Prostate Cancer Prostatic Dis; 2001 Jan 24; 4(1):33-43. PubMed ID: 12497061
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelone, via parenteral or oral route.
    Chou TC, Dong H, Zhang X, Tong WP, Danishefsky SJ.
    Cancer Res; 2005 Oct 15; 65(20):9445-54. PubMed ID: 16230408
    [Abstract] [Full Text] [Related]

  • 20. Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts.
    Newman RA, Yang J, Raymond M, Finlay V, Cabral F, Vourloumis D, Stephens LC, Troncoso P, Wu X, Logothetis CJ, Nicolaou KC, Navone NM.
    Cancer Chemother Pharmacol; 2001 Oct 15; 48(4):319-26. PubMed ID: 11710633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.